Peptide Profile

Semaglutide

GLP-1 Receptor Agonist

Overview

Composition

Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analog of the endogenous incretin hormone GLP-1 with structural modifications (including fatty acid conjugation) that extend its half-life to approximately one week

Mechanism of Action

Enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and exerts central effects to reduce appetite and food intake

Primary Effects

Results in improved glycemic control and substantial body-weight reduction in approved populations, with one of the larger evidence bases in the incretin-mimetic class

Discovery & Background

Developed by Novo Nordisk as an evolution of earlier GLP-1 analogs like liraglutide

FDA approvals began with Ozempic for type 2 diabetes in 2017, Rybelsus as a tablet formulation in 2019, Wegovy for chronic weight management in 2021, cardiovascular-risk reduction for Wegovy in 2024, and MASH with moderate-to-advanced fibrosis in 2025.

FDA-approved for type 2 diabetes, chronic weight management, cardiovascular-risk reduction in adults with cardiovascular disease and overweight/obesity, and Wegovy-specific MASH treatment in adults with moderate-to-advanced fibrosis; other uses are off-label or investigational

Research Overview

Extensive Phase 3 clinical trials (SUSTAIN, STEP, SELECT, and others) involving tens of thousands of participants have established semaglutide's efficacy

01
STEP trials demonstrated clinically significant weight reduction in adults with obesity or overweight with comorbidities
02
Significant HbA1c reductions (1.5–2.0%)
03
Cardiovascular outcome benefits (e.g., SELECT trial showed ~20% relative risk reduction in major adverse cardiovascular events in people with overweight/obesity and established CVD)
04
Wegovy received an FDA MASH indication in adults with moderate-to-advanced fibrosis based on an ongoing Phase 3 trial interim analysis
05
Other liver, cardiometabolic, and inflammatory-marker claims should be separated by indication and endpoint
06
Potential secondary effects in PCOS and other insulin-resistant states
07
Real-world evidence supports these findings, though gastrointestinal tolerability remains a key limitation

FDA-approved for type 2 diabetes, chronic weight management, cardiovascular-risk reduction in the labeled population, and Wegovy-specific MASH treatment in adults with moderate-to-advanced fibrosis; other uses are off-label or investigational

Safety Considerations

Monitoring

Blood glucose/HbA1c
Weight
Lipids
Liver function
Symptom patterns

Side Effects

Gastrointestinal (Common)

Nausea
Vomiting, diarrhea, or constipation
Peak during escalation phase

Local

Local reactions can occur with approved products

Rare but Serious

Pancreatitis
Gallbladder issues
Thyroid concerns (boxed warning for C-cell tumors in rodents)

Contraindications

Personal/family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Known hypersensitivity to semaglutide or any component

Educational Notice

Semaglutide has strong clinical evidence for approved diabetes, weight-management, cardiovascular-risk, and Wegovy-specific MASH indications. Benefits and risks should be interpreted through official labeling and trial populations; compounded or research-market formulations lack the same regulatory oversight.

References